Experimental drug BI 836880 tested in advanced cancer patients
NCT ID NCT02689505
First seen Nov 01, 2025 · Last updated May 20, 2026 · Updated 28 times
Summary
This early-phase trial tested a new drug called BI 836880 in 24 adults with advanced solid tumors that had stopped responding to standard treatments. The main goal was to find the safest dose and check for side effects. Participants received the drug once a week through an IV. The study is complete and helps guide future research.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOPLASMS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
CTR Georges-François Leclerc
Dijon, 21079, France
-
Hospital Vall d'Hebron
Barcelona, 08035, Spain
Conditions
Explore the condition pages connected to this study.